ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

BBOT vs PYXS // OPTIONS IMPLIED MOVE & PUT/CALL SKEW

BridgeBio Oncology Therapeutics Inc. (NASDAQ) VS. Pyxis Oncology Inc. (NASDAQ) • 15-METRIC TALLY: BBOT 0 — PYXS 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BBOT VS. PYXS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC BBOT PYXS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 82.80% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — -14.20% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 3/9 -1.00 PYXS /piotroski-score <GO>
Options Implied Move & Put/Call Skew ACTIVE — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 24.1 34.8 -10.76 PYXS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $216.5M $226.0M -$9.5M PYXS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR BBOT REV PYXS REV BBOT GROSS % PYXS GROSS % BBOT FCF PYXS FCF
FY 2025 $0 $13.9M — 82.8% -$114.5M -$63.5M
FY 2024 $0 $16.1M — 97.1% -$55.1M -$57.9M
FY 2023 $0 $0 — — — -$70.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BBOT // BETA —
PYXS // BETA —